TD Cowen raised the firm’s price target on Fortinet (FTNT) to $135 from $120 and keeps a Buy rating on the shares. The firm said solid demand ...

TD Cowen analyst Shaul Eyal increased the price target on Fortinet stock (NASDAQ:FTNT) to $135 from the previous target of $120, while maintaining a Buy rating on the shares. The adjustment follows ...

Apple supplier Skyworks Solutions saw its stock drop nearly 25% Thursday as the semiconductor firm said that it's losing ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.

Citi analyst Fatima Boolani increased the price target on Fortinet stock (NASDAQ:FTNT) to $115, up from the previous $101, while maintaining a Neutral rating on the shares. The stock, currently ...

TD Cowen analyst Bryan Bergin upgraded Genpact (G) to Buy from Hold with a price target of $60, up from $45. The company’s turnaround traction ...

CFO Jay Malave will participate in a fireside chat at the TD Cowen 46th Annual Aerospace & Defense Conference on Thursday, Feb. 13 at 8:30 a.m. to 9:10 a.m. ET.

TD Cowen's model also assumes that capital expenditures (Capex) will remain at 6% of sales, with a return on invested capital (ROIC) of 23%, which is among the highest in the firm's coverage of ...

The TD Cowen analyst's comments underscore the challenges the company faces in achieving its financial targets. Investors are advised to monitor DarioHealth's performance closely, especially ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics ...